“Concomitant 5-ASA does not appear to impact the efficacy of vedolizumab IV or SC treatment in patients with IBD,” Ungaro and colleagues concluded.

Similarly, maternal use of 5-ASA for CD resulted in an increased but not statistically significant HR for major congenital abnormalities (HR = 1.44; 95% CI, 0.84-2.47).

Therapeutic agents taken within 1 year before neoplasia diagnosis were classified into three types: biologics (infliximab, vedolizumab, golimumab, and adalimumab), 5-aminosalicylic acid (5-ASA ...

Escalation of doses of biologic therapies in IBD may be key to improve patient care, showing a good response rate and ...

The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies, particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear.